Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100VIBY
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥31m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥63m2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥976m2022-01-01 → 2022-12-31dStandaloneNet sales (5-year summary)
Revenue¥642m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥314m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.7bn2024-01-01 → 2024-12-31StandaloneOperating income
Operating income−¥1.9bn2023-01-01 → 2023-12-31StandaloneOperating income
Ordinary income−¥1.7bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.9bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.5bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.7bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.7bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Profit before tax−¥1.9bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Net income−¥1.7bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥1.9bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income−¥1.1bn2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.6bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income−¥2.1bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Total assets¥3.2bnat 2024-12-31StandaloneAssets
Total assets¥2.0bnat 2023-12-31StandaloneAssets
Total assets¥2.7bnat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥4.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥447mat 2024-12-31StandaloneLiabilities
Total liabilities¥567mat 2023-12-31StandaloneLiabilities
Net assets / equity¥2.8bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.5bnat 2023-12-31StandaloneNet assets
Net assets / equity¥2.2bnat 2022-12-31dStandaloneNet assets
Net assets / equity¥3.6bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.0bnat 2020-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.4bnat 2024-12-31StandaloneCash and deposits
Cash and deposits¥1.5bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥2.2bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2022-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥3.2bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.8bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥2.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.7bn2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.7bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥5m2024-01-01 → 2024-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥5m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥20m2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥942,0002021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥38m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥2.9bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥114m2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥3.1bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥242m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-77.172024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-108.922023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-66.312022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-95.52021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-145.582020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥110.4at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥74.35at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥124.2at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥206.86at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥136.43at 2020-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio85.8%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio71.5%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio81.2%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.6%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio71.4%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued24,961,600at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued19,717,100at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,405,200at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued17,405,200at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued14,641,900at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees35at 2024-12-31StandaloneNumber of employees
Employees34at 2023-12-31StandaloneNumber of employees
Employees33at 2022-12-31dStandaloneNumber of employees
Employees33at 2021-12-31dStandaloneNumber of employees
Employees32at 2020-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 794
ItemContextValueUnit
Proceeds from issuance of subscription rights to shares fin cfCurrentYearDuration_NonConsolidatedMember－JPY
Payments for the issuance of stock acquisition rights fin cfPrior1YearDuration_NonConsolidatedMember－JPY
Payments for the issuance of stock acquisition rights fin cfCurrentYearDuration_NonConsolidatedMember-5002000JPY
Net cash provided by used in financing activitiesPrior1YearDuration_NonConsolidatedMember1142542000JPY
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember2879444000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember21334000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember23504000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember-178437000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember878155000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember1466201000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1287763000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1287763000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember2165918000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember101308000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember101053000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember200165000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember212782000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1351940000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1088997000JPY
Business consignment expenses sgaPrior1YearDuration_NonConsolidatedMember84542000JPY
Business consignment expenses sgaCurrentYearDuration_NonConsolidatedMember90665000JPY
Taxes and dues sgaPrior1YearDuration_NonConsolidatedMember25552000JPY
Taxes and dues sgaCurrentYearDuration_NonConsolidatedMember40982000JPY
License fee sgaPrior1YearDuration_NonConsolidatedMember31293000JPY
License fee sgaCurrentYearDuration_NonConsolidatedMember32589000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1351940000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1088997000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2025-03-28
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第21期(自　2024年１月１日　至　2024年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　浦田　泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)経理・財務部長　　米尾　哲治
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)経理・財務部長　　米尾　哲治
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE30058
Fund codeFilingDateInstant－
Security codeFilingDateInstant45880
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Filer name in englishFilingDateInstantOncolys BioPharma Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2023-12-31pass rounding
balance sheet identitynon_consolidated 2024-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass